$1.25 million awarded to progress University of Queensland-developed prostate cancer drug

Development of a new drug based on research at The University of Queensland, targeting advanced and therapy-resistant prostate cancer, has been awarded $1.25 million from the US-based Critical Path Institute’s Translational Therapeutics Accelerator. According to a statement from UQ on Tuesday, the drug named QED-203 has its origins in research by Professor Greg Monteith from…

UQ biotech innovation partnership forges a second startup

A new startup aimed at discovering and developing anti-inflammatory disease medicines has been formed by The University of Queensland’s commercialisation arm UniQuest and global biotech company Molecule to Medicine (MTM), according to a statement released on Tuesday. Curlew Bio will leverage expertise from the Queensland Emory and Drug Discovery Initiative (QEDDI) and research developed by…

UQ expertise bolsters aluminium ion battery tech

The University of Queensland’s Australian Institute for Bioengineering and Nanotechnology is to work with Graphene Manufacturing Group in its quest to commercialise novel Graphene Aluminium-Ion Battery Technology. The development, supported by the federal government’s Economic Accelerator Seed Grant, will accelerate under a partnership between AIBN material chemist Dr Xiaodan Huang (pictured, below) and GMG’s supporting…